Is It Too Late To Consider NewAmsterdam Pharma After Its Strong 2025 Share Price Rally? [Yahoo! Finance]
NewAmsterdam Pharma Company N.V. - Ordinary Shares (NAMS)
Company Research
Source: Yahoo! Finance
The stock is up 5.6% over the last week and 43.5% year to date, with a 50.9% gain over the past year suggesting that sentiment and expectations around the story have shifted significantly. Recent news flow has focused on NewAmsterdam Pharma's progress in late-stage clinical programs and growing investor interest in its pipeline, which has helped support those strong multi-year returns. At the same time, coverage from major brokers and increased institutional attention have contributed to the narrative that this might be a high-growth, higher-risk, but potentially mispriced biotech opportunity. Despite that backdrop, NewAmsterdam Pharma has a valuation score of 4 out of 6 . This suggests the market might not be fully pricing in its potential. In the next sections we will outline the standard valuation approaches investors use here, and then finish with a more powerful way to think about what the stock might be worth. NewAmsterdam Pharma delivered 50.9% returns over the last year
Show less
Read more
Impact Snapshot
Event Time:
NAMS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NAMS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NAMS alerts
High impacting NewAmsterdam Pharma Company N.V. - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
NAMS
News
- NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
- NewAmsterdam Pharma (NASDAQ:NAMS) had its "neutral" rating reaffirmed by analysts at The Goldman Sachs Group, Inc..MarketBeat
- NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in DecemberGlobeNewswire
- NewAmsterdam: Obicetrapib MAA Filings Merit Continued 'Buy' Rating [Seeking Alpha]Seeking Alpha
- NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
NAMS
Sec Filings
- 12/4/25 - Form SCHEDULE
- 12/2/25 - Form 144
- 12/2/25 - Form 144
- NAMS's page on the SEC website